Introduction：Basic information about Diquafosol Tetrasodium CAS 211427-08-6, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Diquafosol Tetrasodium Basic information
| Product Name: | Diquafosol Tetrasodium |
| Synonyms: | INS 365;D03864;Diquafosol sodium;Diquafosol sodium (jan);Diquafosol tetrasodium;Diquafosol tetrasodium (usan);Diquafosol Impurity 7(UP4U);[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate |
| CAS: | 211427-08-6 |
| MF: | C18H27N4NaO23P4 |
| MW: | 814.3 |
| EINECS: | 253-874-2 |
| Product Categories: | |
| Mol File: | 211427-08-6.mol |
|
Diquafosol Tetrasodium Chemical Properties
| storage temp. | Store at -20°C |
| solubility | DMSO:1.0(Max Conc. mg/mL);1.14(Max Conc. mM)
Water:100.0(Max Conc. mg/mL);113.86(Max Conc. mM) |
| form | A solid |
| color | White to off-white |
| Optical Rotation | [α]/D -12.0 to -8.0°, c =1.0 in H2O |
| Water Solubility | H2O: 2mg/mL, clear |
| InChIKey | XPZQVLUPTGTIJP-NIBQMMLDNA-N |
Safety Information
| WGK Germany | WGK 3 |
| Storage Class | 11 - Combustible Solids |
Diquafosol Tetrasodium Usage And Synthesis
| Description | Diquafosol (INS-365) was approved in Japan in 2010 as a 3%ophthalmic solution for treatment of dry eye disease. Clinical diagnosis of dry eye is difficult because the conditionpresents a variety of symptoms. Treatment options include tearsupplements (lubricants), anti-inflammatory drugs (e.g., cyclosporineeye drops or steroid eye drops), and tear retention devices. Diquafosolis a unique agent for the treatment of dry eye in that it acts as a P2Y2purinergic receptor agonist with the ability to activate this receptor onthe ocular surface and stimulate water, lipid, and mucin secretion. Diquafosol is metabolized by phosphodiesterases to UTP, UDP, UMP, and uridine. Diquafosol has been well tolerated in clinical trials, with side effects being local to the ocular surface.In addition,no serious ocular or systemic adverse drug reactions were foundduring the clinical trials. |
| Originator | Inspire Pharmaceuticals (United States) |
| Uses | Enhancement of mucosal hydration in the treatment of chronic dry eye (P2Y2 receptor antagonist). |
| Brand name | Diquas |
| Clinical Use | Diquafosol tetrasodium was approved in April 2010 as Diquas ® ophthalmic solution 3% for thetreatment of dry eye syndrome and launched in Japan by Santen Pharmaceuticals. Diquafosoltetrasodium was originally discovered by Inspire Pharmaceuticals. In 2001, it was licensed to Santenfor co-development and commercialization in Asian countries, and co-developed in collaboration withAllergan for the countries outside of Asia. In the U.S., diquafosol tetrasodium was submitted for a New Drug Application (NDA) as Prolacria ®(2% ophthalmic formulation) in June 2003. However, it is stillin Phase III clinical development for dry eye syndrome. Diquafosol tetrasodium, also known as INS-365, is a P2Y2 receptor agonist, which activates P2Y2 receptor on the ocular surface, leading torehydration through activation of the fluid pump mechanism of the accessory lacrimal glands on theconjunctival surface. |
| Synthesis | The large-scale synthesis route of diquafosol tetrasodium is described inScheme 4. Commercially available uridine 5?ˉ-diphosphate disodium salt (21) was transformedinto the corresponding tributylamine salt by ion exchange chromatography on Dowex 50 using Bu3NH+phase, and then dimerized by means of CDI in DMF at 50 oC. The crude product was purified bySephadex DEAE column followed by ion exchange using a Dowex 50W resin in Na+ mode. The onepotprocess provided diquafosol tetrasodium (IV) in 25% yield. |
Diquafosol Tetrasodium Preparation Products And Raw materials
